SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Report abuse about a comment

Sponsors involved as well

One should not forget that CROs still work for sponsors and do not conduct trials for themselves. The fact that sales outside the US have grown that much demonstrates that the big pharma , which is by far the biggest client of global CROs, is more and more interested in selling its products outside the US market. This is particularly true for emerging countries such as Brasil or India. And since it is way easier to get registration and to sell its drug, in Brasil for example, once trials have been conducted in the country, sponsors ask for CROs to have an international expansion. Therefore it is not only the CROs that are globalising, it is the whole pharma industry.

Posted by Guillaume Miara
30 August 2011 | 15h30

Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.

Your name *
Your email *

We will not publish your email on the site

Reason *

Back to: Over 50% of sales at top CROs now made outside US; report

Spotlight

Evotec confirms orphan drug development status with Shire contract

Evotec teams with Shire on Fabry's disease as pharma interest in orphans grows

Evotec has partnered with Shire to develop inhibitors against Fabry’s disease and says such collaborations will grow...

CRL nears 85% capacity use, but says sector pricing won't improve yet

CRL nears 85% capacity use, but says sector pricing won't improve yet

Charles River Laboratories is approaching its optimal capacity utilisation but says pricing will not improve until the...

CMO issues persist as Cubist announces third recall for antibiotic

CMO issues persist as Cubist announces third recall for potential glass in antibiotic

For the third time since last August, Cubist Pharmaceuticals has recalled lots of its antibiotic Cubicin injection...

AMRI: Big Pharma still reliant on CMOs for sterile injectables

Injectables outsourcing growing despite pharma M&A, says AMRI

Big Pharma is still reliant on CMOs despite talk of returning in-house, says AMRI, which has launched...

Quintiles sees strong demand from large pharma

Quintiles sees strong demand from large pharma

Quintiles CEO Tom Pike told investors last week that the company is seeing “very strong demand from...

Almac announces Government backed recruitment drive

Almac announces Government backed recruitment drive

Northern Ireland-based contractor Almac will create 348 jobs over the next five years in its pharma and...